Floatz logo

Prostvac®-Vf/Tricom™

Liver Neoplasms

National Cancer Institute (NCI)vaccinePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

18 Active assets in the Liver Neoplasms cohort.

Asset / SponsorPhaseRating
Irinotecan
Tehran University of Medical Sciences
Phase 4BBB
Calcium folinate pentahydrate
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 4BB
Eloxatin
Shanghai Zhongshan Hospital
Phase 4BB
Talaporfin
Light Sciences Oncology
Phase 3BB
FLUOROURACILUM
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 4BB

View all 50 →

Same molecule, other indications

Prostvac®-Vf/Tricom™ is also rated in:

prostate neoplasmDormant
BB
Indicative ·
65 / 100
View asset →
prostate cancerDormant
B
Indicative ·
62 / 100
View asset →
metastatic prostate carcinomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →